Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q3 FY26
Bearish
6
Neutral
4
Bullish
4
Bearish
8
Neutral
4
Bullish
34
Bearish
2
Neutral
0
Bullish
30
Discovery themes featuring this stock
Innovassynth Technologies is an integrated chemical company providing Life Sciences & Nucleosides, Specialty Chemicals and CRDMO (Contract Research, Development & Manufacturing) services from a multi-plant manufacturing campus near Khopoli, India, serving over 100 global customers with an export-led business model focused on the US and EU markets.
Financially, Q3 FY26 revenue was INR 22 Crore with YTD FY26 revenue of INR 52 Crore, but the company reported operating losses (EBITDA loss of INR 4.5 Cr in Q3 and YTD EBITDA loss INR 31 Cr) and PAT losses, reflecting weak near-term profitability despite a substantial order book and product commercialization pipeline.
Operationally, Innovassynth operates 9 multipurpose plants on a 60+ acre campus, supported by 50+ scientists including 10+ PhDs, and emphasizes backward integration and process improvements to enhance yields; these capabilities position the company to scale CRDMO and specialty life science manufacturing when order conversion accelerates.
Geography shifts are notable: export concentration remains high but regional mix changed materially in YTD FY26 from the prior year with USA share falling to 39% and EU rising to 35%, while ROW contributes 26%, indicating customer and revenue diversification that could reduce single-market concentration risk.
Sustainability credentials include consecutive Ecovadis Gold ratings and initiation of SBTi in 2026, while quality systems are robust (ISO 27001, 14001, 45001, 9001), signaling management’s intent to align manufacturing, compliance and ESG commitments with international customer expectations and tender eligibility.
Finance
Investment Company
599 Cr
Low Risk
64.7
19.3
—
7.7
139.85
50.10
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stock
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Innovassynth Technologies (India) Ltd (INOVSYNTH) is currently trading at 78.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Innovassynth Technologies is an integrated chemical company providing Life Sciences & Nucleosides, Specialty Chemicals and CRDMO (Contract Research, Development & Manufacturing) services from a multi-plant manufacturing campus near Khopoli, India, serving over 100 global customers with an export-led business model focused on the US and EU markets. Financially, Q3 FY26 revenue was INR 22 Crore with YTD FY26 revenue of INR 52 Crore, but the company reported operating losses (EBITDA loss of INR 4.5 Cr in Q3 and YTD EBITDA loss INR 31 Cr) and PAT losses, reflecting weak near-term profitability despite a substantial order book and product commercialization pipeline. Operationally, Innovassynth operates 9 multipurpose plants on a 60+ acre campus, supported by 50+ scientists including 10+ PhDs, and emphasizes backward integration and process improvements to enhance yields; these capabilities position the company to scale CRDMO and specialty life science manufacturing when order conversion accelerates. Geography shifts are notable: export concentration remains high but regional mix changed materially in YTD FY26 from the prior year with USA share falling to 39% and EU rising to 35%, while ROW contributes 26%, indicating customer and revenue diversification that could reduce single-market concentration risk. Sustainability credentials include consecutive Ecovadis Gold ratings and initiation of SBTi in 2026, while quality systems are robust (ISO 27001, 14001, 45001, 9001), signaling management’s intent to align manufacturing, compliance and ESG commitments with international customer expectations and tender eligibility.
Over the past 52 weeks, Innovassynth Technologies (India) Ltd has traded between a low of ₹50.10 and a high of ₹139.85. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Innovassynth Technologies (India) Ltd has a market capitalization of approximately 598.54. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Innovassynth Technologies (India) Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 64.74 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 598.54 Cr, Innovassynth Technologies (India) Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Innovassynth Technologies (India) Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Innovassynth Technologies (India) Ltd is 64.74. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
239.00 | 761 Cr | 13.22 | 0.29 | 0.67 | -0.75 | -1.07 | 1.92 | ||
24.90 | 749 Cr | 15.18 | 0.30 | 0.00 | 0.48 | 0.61 | 0.79 | ||
79.00 | 599 Cr | 64.74 | 7.70 | 0.00 | -15.71 | -12.27 | -12.77 | ||
440.00 | 570 Cr | 22.98 | 5.82 | 0.00 | 35.33 | 41.23 | 26.17 | ||
398.00 | 498 Cr | 9.54 | 0.17 | 0.53 | 1.34 | 1.79 | 1.38 | ||
1260.00 | 470 Cr | 145.66 | 0.64 | 0.00 | 0.46 | 0.61 | 0.38 | ||
239.75 | 420 Cr | 6.07 | 0.25 | 0.60 | 3.61 | 4.17 | 3.62 | ||
| Median: 7 Co. | — | 239.75 | 570 Cr | 15.18 | 0.30 | 0.00 | 0.48 | 0.61 | 1.38 |
Rights Issue Meeting
Innovassynth has scheduled a Rights Issue Committee meeting on Apr 23, 2026 to decide specific terms (price, payment mechanism, entitlement ratio, fractional entitlements, record date and timing) for the previously approved ~₹70 Cr rights issue, subject to regulatory approvals.
Rights Issue Intimation
Innovassynth Technologies scheduled a Rights Issue Committee meeting on Apr 23, 2026 to finalise terms (price, entitlement ratio, fractional entitlement, record date, payment mechanism and timing) for a previously approved rights issue of up to ₹70 crore, subject to in‑principle BSE approval.
